ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1219 • ACR Convergence 2025

    Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy

    Vasiliki Syrmou1, Ioannis Alexiou2, Christos Liaskos3, Eleni Patrikiou3, THEODORA SIMOPOULOU4, Christina Katsiari5 and Dimitrios Bogdanos6, 1University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, 2University General Hospital of Larisa, Larissa, Greece, 3University of Thessaly, Faculty of Medicine, Larisa, Greece, 4University Hospital of Larissa, Greece, Larissa, Greece, 5University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, 6Professor, Larissa, Greece

    Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
  • Abstract Number: 1002 • ACR Convergence 2025

    ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells

    Xiao Zhang1, linmang Qin2 and Yixuan Li1, 1The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China (People's Republic), 2Sun Yat-sen University, gaungzhou, Guangdong, China (People's Republic)

    Background/Purpose: The rising incidence of connective tissue disease-associated interstitial lung disease (CTD-ILD) significantly worsens patient prognosis. While its pathogenesis remains unclear, immune-inflammatory dysregulation—particularly enhanced immune…
  • Abstract Number: 0435 • ACR Convergence 2025

    Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study

    Ahmad Alomari1, Reem Elmusa2, Nikita Shah3, Miguel Rodriguez4 and Diala Alawneh5, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/ HCA - North florida hospital, Gainesville, FL, 3UCF/HCA Florida North Florida Hospital, Gainesville, FL, 4SIMED Rheumatology, Gainesville, FL, 5University of Florida, Gainesville, FL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
  • Abstract Number: 2265 • ACR Convergence 2025

    Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients

    Ana Serrano-Combarro1, Belén Atienza-mateo2, Adrian Martin-Gutierrez3, Marta López-Maraver4, Libe Ibarrola5, Ivette Casafont-Solé6, Jesús Loarce7, Juan María Blanco-Madrigal8, Santos Castañeda9, Rafaela Ortega-Castro10, Natalia Mena Vázquez11, Nuria Vegas Revenga12, Lucia C. Domínguez-Casas13, Cilia Peralta-Ginés14, Carlos Fernández Díaz15, Javier Loricera16 and Ricardo Blanco17, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 4Hospital Universitario Araba, Vitoria, Spain, 5Galdakao-Usansolo University Hospital, GALDAKAO, Spain, 6Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Ramón y Cajal University Hospital, Madrid, Spain, 8Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, 9Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 11Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, 12Galdakao- Usansolo University Hospital, Galdakao, Spain, 13Hospital Universitario San Agustin, Aviles, Spain, Aviles, 14Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 15H.U. Santa Lucia, Murcia, Spain, 16Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 17Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
  • Abstract Number: 2047 • ACR Convergence 2025

    Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades

    Sambhawana Bhandari1, Derek E. Byers1 and Deepali Sen2, 1Washington University in St. Louis School of Medicine, St. Louis, 2Washington University in St Louis, Chesterfield, MO

    Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
  • Abstract Number: 1778 • ACR Convergence 2025

    Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers

    Verónica Pulito Cueto1, Joao Carlos Batista-Liz1, Rebeca Nieto-Nieto2, Clara Vaquera-Illescas2, Diego San Emeterio-Villar2, Daniel Vicente-Mínguez2, María Sebastián Mora-Gil2, Belén Atienza-mateo3, Ana Serrano-Combarro4, David Iturbe-Fernández5, Victor M. Mora-Cuesta5, Carolina Aguirre-Portilla4, Jose M Cifrián5, Ricardo Blanco4 and Raquel Lopez Mejias1, 1IDIVAL, Santander, Spain, 2Immunopathology Group, IDIVAL, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, 4Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
  • Abstract Number: 1567 • ACR Convergence 2025

    Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease

    Enrico De Lorenzis1, Rosa D'Abronzo2, Pier Giacomo Cerasuolo3, Lucio Calandriello4, Gabriella Alonzi3, Giuseppe Cicchetti2, gerlando Natalello3, Bruno Iovene5, Lucia Lanzo3, Francesco Varone6, Giacomo Sgalla7, Luca Richeldi8, anna Rita Larici4, Maria Antonietta D'Agostino3 and Silvia Laura Bosello9, 1Catholic University of the Sacred Heart, Roma, Rome, Italy, 2Division of Radiology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, 3Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 4Division of Radiology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, 6Division of Respiratory Medicine - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, 8Division of Respiratory Medicine - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, 9Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy

    Background/Purpose: Interstitial lung disease (ILD) is a major complication in systemic sclerosis (SSc) patients, associated with substantial morbidity and mortality. Functional, imaging, and clinical measures…
  • Abstract Number: 1217 • ACR Convergence 2025

    Validation and clincial use of anti-MDA5 test – LIA versus ELISA

    TING-YUAN LAN1, pei-Hsinq lai2, Tai-Ju Lee3, Ting-Wei Chang4, Kuan-Yen Lin5, Shao-Yu Pai6 and Ko-Jen Li7, 1National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, 2Taipei City Hospital, Taichung, Taiwan, 3National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), 4National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, 5National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), 6National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), 7National Taiwan University Hospital, Taipei, Taiwan

    Background/Purpose: Although immunoprecipitation (IP) remains the gold standard for detecting myositis autoantibodies, it is technically demanding and not widely available. Line immunoassay (LIA) has become…
  • Abstract Number: 0973 • ACR Convergence 2025

    Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.

    Takuya Kotani1, Takayasu Suzuka2, Shogo Matsuda3 and Tohru Takeuchi4, 1Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, 2Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Takatsuki, Japan, 3Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, 4Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan

    Background/Purpose: S100 proteins are involved in the inflammatory responses of autoimmune diseases. We previously showed that S100 proteins regulate macrophage function via CD68. Based on…
  • Abstract Number: 0430 • ACR Convergence 2025

    Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD

    fatih ŞAhiner1, Mine Nokay2, funda erbasan2, Veli Yazisiz3 and Ender terzioglu2, 1Akdeniz University, Antalya, 2Akdeniz University, Antalya, Turkey, 3Akdeniz University, Faculty of Medicine, Antalya, Turkey

    Background/Purpose: RA-ILD is significant determinants of morbidity and mortality. This study aims to evaluate the demographic and serological characteristics of RA-ILD patients and investigate the…
  • Abstract Number: 2262 • ACR Convergence 2025

    Assessment of small airway disease in rheumatoid arthritis

    Stéphane HILLIQUIN1, Huy-Thong HUA2, Hà Pham-Ngoc2, Frédérique Aubourg2, Nhât-Nam Lê-Dông2, Sven Günther3, Nicolas ROCHE4, Jérôme AVOUAC5, Yannick Allanore6 and Anh-Tuan Dinh-Xuan2, 1Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, 2Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 3Unité exploration fonctionnelle respiratoire, Georges-Pompidou Hospital, APHP, PARIS, France, 4Pneumology department, Cochin Hospital, APHP, PARIS, France, 5Rheumatology department, Cochin hospital, Paris, France, 6Université Paris Cité, Paris, France

    Background/Purpose: The risk of interstitial lung disease is well established in Rheumatoid Arthritis (RA). Less is known about the airway involvement which has been estimated…
  • Abstract Number: 2031 • ACR Convergence 2025

    Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives

    Genna Braverman1, Kerri Aronson2, Charlene Thomas2 and Robert Spiera3, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell, New York, NY, 3Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: Interstitial lung disease (ILD) is common and important feature of systemic autoimmune rheumatic diseases (SARD). Rheumatologists and pulmonologists are central to the care of…
  • Abstract Number: 1751 • ACR Convergence 2025

    Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study

    Gregory McDermott1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Emily Kowalski5, Grace Qian6, Liya Sisay Getachew5, Kevin Mueller6, Alene Saavedra6, Lauren O'Keeffe6, Natalie Davis1, Alison Puri7, Kathleen Vanni6, Caleb Bolden8, Tina Mahajan9, Erica Mulcaire-Jones10, Neda Kortam11, Pierre Antoine Juge12, Tracy J. Doyle13, Marcy Bolster14, Kevin Deane15, Dinesh Khanna10, Bryant England9, Raul San Jose Estepar6, George Washko6 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, 7Boston University, Brookline, MA, 8Massachusetts General Hospital, Boston, 9University of Nebraska Medical Center, Omaha, NE, 10University of Michigan, Ann Arbor, MI, 11University of Michigan, Ann Arbor, 12Hopital Bichat, APHP, Paris, France, 13Brigham and Women's Hospital, West Roxbury, MA, 14Massachusetts General Hospital, Concord, MA, 15University of Colorado Denver Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect…
  • Abstract Number: 1564 • ACR Convergence 2025

    Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease

    Elizabeth Volkmann1, Holly Wilhalme2, Samuel Good2, Grace Kim2, Jonathan Goldin2, Michael Roth2 and Donald Tashkin2, 1Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, 2UCLA, Los Angeles

    Background/Purpose: The forced vital capacity (FVC) is the most commonly used endpoint in registrational trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, the FVC…
  • Abstract Number: 1213 • ACR Convergence 2025

    Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)

    Sangmee Bae1, Grace Kim2, Jihey Lee2, Daniela Markovic2, Donald Tashkin2, Jonathan Goldin2, Rohit Aggarwal3 and Christina Charles-Schoeman4, 1UCLA Rheumatology, Los Angeles, CA, 2UCLA, Los Angeles, 3University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, 4UCLA Medical Center, Santa Monica, CA

    Background/Purpose: HRCT is used as a surrogate for important histopathological findings when evaluating patients with interstitial lung disease (ILD). Quantitative imaging analysis (QIA) using CT…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 47
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology